Adalta Ltd has released a press release.
AD-214 pathway to IPF efficacy studies
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from AdAlta
- AdAlta secures AD-214 resupply
- R&D Tax Incentive Facility
- GE Healthcare collaboration advances to next stage
- AdAlta granted Japanese patent for AD-214
- Mutiple Dose Part Of Ad-214 Phase I Trial Commenced
Later from AdAlta
- Webinar and presentation on AD-214 strategy
- CAR-T collaboration with Carina Biotech
- Carina collaboration webinar presentation
- $4.0M Non-Dilutive Financing with Victorian Government
- Corporate overview and IRD Invest 2021 presentation
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta